In particular, when PC has become castration-resistant, PSA cannot be considered the best indicator of response to therapy, due to the increase in cancer cell heterogeneity with the presence of PSA-producing and nonproducing cells and the presence of flare phenomena as a result of therapy response. This evidence concerns the gene KLK3 and cancer.